[Vasopeptidase inhibitors. Clinical implications of a new class of drugs].
Quaschning
T
T
Abteilungen für Kardiologie und Kardiovaskuläre Forschung, Universitätsspital Zürich, Schweiz.
Corti
R
R
Ruschitzka
F T
FT
Noll
G
G
Lüscher
T F
TF
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D009320:Atrial Natriuretic Factor / Q000097:blood; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D004195:Disease Models, Animal; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D015260:Neprilysin / Q000037:antagonists & inhibitors*; D012084:Renin-Angiotensin System / Q000187:drug effects
D000806:Angiotensin-Converting Enzyme Inhibitors; D009320:Atrial Natriuretic Factor; D015260:Neprilysin